Getinge AB stock (SE0000202624): shares steady on Nasdaq Stockholm as new Vasoview Hemopro 3 launch underpins surgical portfolio

Getinge AB shares were little changed on Nasdaq Stockholm on 06/03/2026 as the Sweden-based medtech group highlighted the recent launch of its Vasoview Hemopro 3 endoscopic vessel harvesting system, adding to its cardiovascular surgery offering in core hospital markets.

Getinge AB traded broadly in line with the wider Swedish healthcare segment on Nasdaq Stockholm on 06/03/2026, with the B share changing hands around SEK 185 per share in Stockholm, while investors continued to digest the group’s recent portfolio news in cardiovascular surgery, including the launch of its Vasoview Hemopro 3 endoscopic vessel harvesting system for hospitals and cardiac surgery centers, according to MarketScreener as of 06/03/2026.MarketScreener as of 06/03/2026

The Sweden-based medical technology group, whose primary listing is on Nasdaq Stockholm, is a component of the broader Nordic healthcare universe and remains a key local name for investors following hospital capital expenditure trends in the country and across Europe, with the Vasoview Hemopro 3 launch underlining its strategy to broaden minimally invasive surgical tools, according to a recent product announcement.MarketScreener as of 05/21/2026

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology and healthcare equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Europe, North America, Asia-Pacific hospitals and life science institutions
• Key revenue drivers: Acute care therapies, surgical workflows, and life science solutions for hospitals and research facilities
• Home exchange/listing venue: Nasdaq Stockholm (GETI B)
• Trading currency: SEK

Getinge AB: core business model

Getinge AB focuses on equipment and solutions for operating rooms, intensive care and sterile reprocessing, with sales driven largely by hospital investment cycles in acute care therapies, surgical workflows and life science applications.

Getinge AB in peer comparison

As a Nordic medtech name, Getinge AB is often compared with European healthcare equipment peers such as Germany’s Drägerwerk and global surgical and patient monitoring manufacturers including Philips and Medtronic, which also target operating room and critical care environments, according to sector overviews from MarketScreener and MarketsandMarkets as of 2026.MarketsandMarkets as of 2026

Industry research indicates that patient monitoring and related medical device markets are projected to grow at mid-single to high-single-digit compound annual rates through 2029, providing a broad demand backdrop that also affects capital spending on intensive care ventilators, anesthesia equipment and surgical tools where Getinge AB competes alongside larger multinational groups, according to MarketsandMarkets as of 2024.MarketsandMarkets as of 04/30/2024

Conclusion

The latest trading session left Getinge AB shares broadly stable on Nasdaq Stockholm, with investors monitoring both the Swedish healthcare macro environment and the company’s incremental product news in cardiovascular surgery. The Vasoview Hemopro 3 endoscopic vessel harvesting system adds another specialized tool to the group’s surgical workflows franchise and supports its competitive stance versus European and global medtech peers. Market attention is likely to remain on how such portfolio additions and broader hospital spending trends translate into revenue growth and profitability over coming reporting periods.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.